A rule change explains the timing, not the cohort's substance

The five-name post-acute cohort in this Healthcare > Medical - Care Facilities > Home Health & Hospice sample — Addus HomeCare, Aveanna Healthcare, Chemed, Enhabit and Option Care Health — carries a headline gain of +54.1% over twelve months. That number is real but misleading: it blends a private-equity buyout, a distressed-balance-sheet rebound, one clean fundamental beat, and one stock still down for the year despite steady earnings.

Every active name's trend band was bearish for most of the first half of 2026 and flipped bullish almost simultaneously in the back half of July — a pattern that lines up with CMS's newly proposed CY2027 home health payment rule, which for the first time since 2022 drops the recurring "behavioral adjustment" cut, instead proposing a temporary -3.0% adjustment against a net +2.4% aggregate payment increase, Applied Policy reports. That is a genuine, dateable catalyst — but a two-to-four-week-old one, not confirmation of a mature re-rating.

Five names, five different stories

Enhabit, a home health and hospice operator spun off from Encompass Health in 2022, no longer trades: Kinderhook Industries agreed in February 2026 to take it private for $13.80/share cash, a roughly 24% premium, and the deal closed in May 2026 — its prior-year "gain" reflects a buyout price, not a functioning market.

Chemed, whose VITAS Healthcare hospice segment sits alongside its unrelated Roto-Rooter plumbing business, is the cleanest fundamental story: second-quarter revenue rose 8.8% year-over-year to $673.3M, VITAS admissions rose 9% and average daily census hit a record above 24,000 in second-quarter results, while Florida's Medicare-cap overhang eased and full-year VITAS census guidance was raised, even as Roto-Rooter faced rising customer-acquisition costs. Chemed trades at a trailing 23.8x, forward 17.5x, with adjusted EBITDA margin guided to 21.5%-22.5% — a reasonable multiple against raised guidance, closer to a supported advance than a stretched one.

Aveanna Healthcare, a pediatric and adult private-duty nursing and home-health provider, raised 2026 guidance after closing the Family First Homecare deal and cut leverage from above 11x to under 3.8x, with ten state Medicaid rate enhancements won in 2025. Its 136% one-year gain, though, comes off a genuinely distressed $3.97 base; at a 13.9x forward multiple it also carries a wide dispersion of valuation opinion, with one model flagging it as significantly overvalued.

Option Care Health, the largest independent home and alternate-site infusion therapy provider, is the outlier: shares are still down 21.5% over twelve months and only exited a bearish trend band in the final days of July. Yet second-quarter revenue grew roughly 2% to $1.4bn and adjusted EBITDA rose 3%, guidance was maintained, and the company repurchased $150M of stock — against a forward multiple near 12.2x, below both Chemed's and its own prior trailing multiple. That combination — a still-depressed price, stable-to-growing earnings, and no visible deterioration — is closer to a dislocation than a confirmed re-rating.

Addus HomeCare, a Medicaid-funded personal home-care and hospice provider, sits opposite: revenue growth decelerated sharply to 7.7% from 21.8% in its most recent quarter, missing estimates, and analysts cut price targets citing regulatory and M&A uncertainty — even as its trend band flipped bullish only two weeks ago. State rate increases have helped (Illinois +3.9%), but Medicaid tightening under the federal budget law is projected to cut enrollment by roughly 7.6 million people by 2034, a structural headwind for its core volumes. Addus reports Q2 results on August 3.

Sector-wide, Medicare Advantage penetration crossed 54% in 2025 and is pushing volume from skilled nursing into the home, though MA rates run 10-15% below fee-for-service, compressing margins even as volume rises — consolidation appetite remains real, illustrated by UnitedHealth's $3.3bn Amedisys close last August alongside the Enhabit deal.

The setup

Where it stands — Cohort trend bands flipped bullish together in late July after a milder CMS CY2027 rule; fundamentals diverge sharply by name. Would confirm — Addus's August 3 print shows revenue growth stabilizing and Option Care's next quarter sustains EBITDA growth with maintained guidance. Would invalidate — Addus growth decelerates further or Option Care's trend band reverses back into a bearish reading within weeks. Watch next — Addus HomeCare reports Q2 2026 results August 3, 2026; CMS finalizes the CY2027 home health rule later this year. Valuation — CHE 23.8x trailing/17.5x forward; AVAH 13.9x forward; OPCH ~12.2x forward versus its own higher trailing multiple; ADUS ambiguous pending Q2.